EYEN Eyenovia Inc

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

Company to host an investor conference call and webcast at 4:30pm EDT

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology company, today announced that the Company will release financial results for the fourth quarter ended December 31, 2023 on Monday, March 18th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operating results.

Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and referencing conference ID 13744365.

To access the Call me™ feature, which avoids having to wait for an operator, click .

A live webcast of the conference call will also be available and on the investor relations page of the Company's corporate website at .

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery, which was approved by the FDA on March 4, 2024.

Eyenovia is also advancing late-stage development of medications in the Optejet device for myopia progression (MicroPine) and presbyopia (Apersure) Both products are partnered with Arctic Vision in China and South Korea.

For more information, visit .

The Eyenovia Corporate Information slide deck may be found at .

PLEASE GO TO CLOBETASOLBID.COM FOR IMPORTANT SAFETY INFORMATION for CLOBETASOL PROPRIONATE OPHTHALMIC SUSPENSION 0.05%

PLEASE GO TO MYDCOMBI.COM FOR IMPORTANT SAFETY INFORMATION for MYDCOMBI™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%

Eyenovia Contact:

Eyenovia, Inc.

John Gandolfo

Chief Financial Officer

Eyenovia Investor Contact:

Eric Ribner

LifeSci Advisors, LLC



(646) 751-4363

Eyenovia Media Contact:

Eyenovia, Inc.

Norbert Lowe

Vice President, Commercial Operations



EN
11/03/2024

Underlying

EYENEyenovia Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eyenovia Inc

 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion DeFi Announces Private Lending Pool Built by HyperLend

Hyperion DeFi Announces Private Lending Pool Built by HyperLend Unlocks Cost-Optimized On-Chain Credit Access, Additional Ecosystem Rewards, and Expanded Revenue Opportunities in Institutional Credit LAGUNA HILLS, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”) today announced that it has engaged with the HyperLend protocol (“HyperLend”) to create a permissioned lending pool native to the HyperEVM. Through this pool, Hyperion DeFi will utilize its HYPE Liquid Staking Token (LST), HiHYPE, as collateral to access credit on-...

March 9, 2026 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion DeFi Announces Institutional Volatility Income Vault Built on...

Hyperion DeFi Announces Institutional Volatility Income Vault Built on Rysk Protocol Productizes On-chain Strategy Designed to Enhance Yield and Ecosystem Rewards through Gated Institutional Access LAGUNA HILLS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”) today announced that it has engaged with the Rysk protocol (“Rysk”) to launch a new institutional-grade, on-chain yield-enhancement vault native to the HyperEVM. Through this vault, Hyperion DeFi and its institutional partners will be able to utilize HYPE Liquid Staki...

February 4, 2026 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion DeFi Issues Letter to Shareholders

Hyperion DeFi Issues Letter to Shareholders LAGUNA HILLS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”) today issued a letter to shareholders from its Chief Executive Officer, Hyunsu Jung. To the shareholders of Hyperion DeFi, Inc.: Let me start by expressing my sincere gratitude to those sharing in our journey to become the leading Hyperliquid-native Decentralized Finance (“DeFi”) company. As I formally step into the CEO role at Hyperion DeFi, I wanted to take a moment to reflect on what we’ve built in 2025 and what we l...

January 12, 2026 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer

Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer Board Confirms Leadership Team to Execute 2026 Strategic Priorities Company Also Appoints Robert Rubenstein as General Counsel LAGUNA HILLS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”) today announced that its Board of Directors has appointed Hyunsu Jung as Chief Executive Officer, effective immediately. Mr. Jung’s appointment marks an important milestone in the Company’s leadership evolution as it advances its strategic priorities for 2026. Mr. Jung joined ...

January 5, 2026 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion DeFi Announces Receipt of Kinetiq Airdrop, Partnership with N...

Hyperion DeFi Announces Receipt of Kinetiq Airdrop, Partnership with Native Markets, and Purchase of 150,000 Additional HYPE Receives 1,918,478.78 KNTQ in the Token Generation Event Airdrop, Plus Right to Earn Additional Yield on 28,888 HYPE Staked by the Company Partnership with Native Markets to Support Hyperliquid-Aligned USDH Stablecoin Generates Additional Yield for 300,000 HYPE Staked by the Company Announces 150,000 HYPE purchase resulting in 1,862,195 Gross HYPE Tokens Owned by the Company LAGUNA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD...

December 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch